Trial Search Results

Sit Less, Interact and Move More (SLIMM) 2 Study

- Prolonged sitting (sedentary behavior) is a risk factor for decreased kidney function, obesity, diabetes and mortality. Prolonged sitting is associated with decreased kidney function and increased risk of diabetes, heart disease and death.

- In a previous pilot study funded by NIH, it was shown that a Sit Less, Interact and Move More (SLIMM) intervention targeting sedentary behavior in people with kidney disease was able to decrease prolonged sitting but that effect was not sustained.

- Therefore, the researchers are currently conducting a follow-up study named Sit Less, Interact and Move More (SLIMM) 2.

- This NIH funded study is conducted at the University of Utah and Stanford University.

- The purpose of this study is to see if guided resistance training (to improve muscle strength) and semaglutide (FDA approved diabetes and weight loss medication that might also improve physical function) can boost adherence to the SLIMM Intervention and reduce sedentary behavior.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Srinvasan Beddhu

Collaborator: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Stanford Investigator(s):


  • Behavioral: SLIMM
  • Behavioral: Standard Resistance Training
  • Behavioral: Guided Resistance Training
  • Drug: Placebo
  • Drug: Semaglutide


Phase 2


Inclusion Criteria:

   - Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) Glomerular Filtration Rate
   (eGFR) 20 to <45 mL/min/1.73m^2

   - Body Mass Index ≥ 27 kg/m^2

   - Six minute walk distance ≥ 300 m and < 600 m

   - Able to perform resistance training

Exclusion Criteria:

   - Clinical history of Type 1 or Type 2 Diabetes Mellitus

   - Screening hemoglobin A1C ≥ 6.5%

   - Potential contraindications to semaglutide such as a history of pancreatitis, family
   or personal history of multiple endocrine neoplasia type 2 or familial medullary
   thyroid carcinoma

   - Previous bariatric surgery

   - Use of medications that cause clinically significant weight gain or loss

   - Medical condition likely to limit survival to less than 1 year

   - Anticipated start of dialysis or kidney transplantation within 6 months

   - Any factors judged by the investigator or study team to likely limit adherence to

   - Vulnerable populations, including pregnant or incarcerated subjects

   - Currently enrolled in interventional clinical trials using drugs or devices

   - Recent hospitalizations or major interventional procedures done within the past 60

Ages Eligible for Study

20 Years - N/A

Genders Eligible for Study


Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Edison Lee